Background: The aim of the study was to evaluate the potential of manganese-zinc ferrite nanoparticles (MZF NPs) as a novel negative magnetic resonance imaging (MRI) contrast agents for 4T1 (mouse mammary carcinoma) and L929 (murine fibroblast) cell lines.
Methods: MZF NPs and its suitable coating, polyethylene glycol (PEG) via covalent bonding, were investigated under condition. The cytotoxicity of MZF NPs was tested by 3-(4,5-dimethyl thiazolyl-2)-2,5-diphenyltetrazolium bromide assay after 12 and 24 h of incubation. To evaluate the potential of MZF NPs as T MRI nanocontrast agent, images were obtained from phantom containing different Fe concentrations and T relaxivity ( ) was measured. The viability of both 4T1 breast cancer and L929 murine fibroblast cell lines incubated with different Fe concentrations.
Results: T-weighted MRI showed that signal intensity of 4T1 cells was lower than that of L929 as control cells. T-weighted MRI showed that signal intensity of MZF NPs enhanced with increasing concentration of NPs. The values of 1/T relaxivity ( ) for coated MZF NPs with PEG found to be 85.5 mM s which is higher than that of commercially clinical used (Sinerem) MRI contrast agent.
Conclusion: The results showed that MZF NPs have potential to detect breast cancer cells (4T1) and also have high contrast resolution between normal (L929) and cancerous cells (4T1) which is a suitable nanoprobe for T-weighted MR imaging contrast agents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839441 | PMC |
| http://dx.doi.org/10.4103/jmss.JMSS_59_18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of S2.2/DOX Magnetic Nanoliposomes in MR Molecule Imaging and Targeted Thermochemotherapy for Breast Cancer In Vitro.
Technol Cancer Res Treat
November 2023
Clinical Laboratory, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
Objective: To prepare S2.2/DOX magnetic nanoliposomes by combining the potential benefits of MNPs in MRI and the targeted performance of nano-drugs as an innovative method for integrated diagnosis and treatment of breast cancer (BC).
Methods: We created a S2.
Novel MR imaging nanoprobe for hepatocellular carcinoma detection based on manganese-zinc ferrite nanoparticles: in vitro and in vivo assessments.
J Cancer Res Clin Oncol
July 2023
Novel Drug Delivery Systems Research Centre and Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Purpose: Achieving new contrast enhancer agents that can produce high-resolution images in magnetic resonance imaging (MRI) with a minimum dose and side effects has always been important.
Methods: Herein, the pegylated curcumin-coated manganese-zinc ferrite nanoparticles (MZF@CA-PEG-CUR NPs) have been reported as an MR imaging nanoprobe in hepatocellular carcinoma detection in the murine model for the first time. In vitro studies were done on HEPA 1-6 cancer cells and L929 as normal cells, and in vivo studies were done on hepatocellular carcinoma (HCC) using xenograft models of HCC.
The Therapeutic Effects of DDP/CD44-shRNA Nanoliposomes in AMF on Ovarian Cancer.
Front Oncol
March 2022
Clinical Laboratory, Taizhou People's Hospital Affiliated to Nanjing University of Chinese Medicine, Taizhou, China.
Background: Globally, ovarian cancer is one of the most common gynecological malignant tumors, and the overall curative effect has been unsatisfactory for years. Exploring and investigating novel therapeutic strategy for ovarian cancer are an imperative need.
Methods: Using manganese zinc ferrite nanoparticles (PEG-MZF-NPs) as gene transferring vector and drug delivery carrier, a new combinatorial regimen for the target treatment of ovarian cancer by integrating CD44-shRNA, DDP (cisplatin) and magnetic fluid hyperthermia (MFH) together was designed and investigated and in this study.
Assessment of Manganese-Zinc Ferrite Nanoparticles as a Novel Magnetic Resonance Imaging Contrast Agent for the Detection of 4T1 Breast Cancer Cells.
J Med Signals Sens
October 2019
Department of Radiology, Askarieh Hospital, Isfahan, Iran.
Background: The aim of the study was to evaluate the potential of manganese-zinc ferrite nanoparticles (MZF NPs) as a novel negative magnetic resonance imaging (MRI) contrast agents for 4T1 (mouse mammary carcinoma) and L929 (murine fibroblast) cell lines.
Methods: MZF NPs and its suitable coating, polyethylene glycol (PEG) via covalent bonding, were investigated under condition. The cytotoxicity of MZF NPs was tested by 3-(4,5-dimethyl thiazolyl-2)-2,5-diphenyltetrazolium bromide assay after 12 and 24 h of incubation.
Assessment of aggregative growth of MnZn ferrite nanoparticles.
Nanoscale
November 2016
Department of Chemistry, State University of New York at Binghamton, Binghamton, NY13902, USA.
MnZn ferrite (MnZnFeO, MZF) nanoparticles (NPs) represent an intriguing class of magnetic NPs in terms of composition-tunable magnetic properties, but the ability to control the size and morphology is essential to exploit such properties. This report describes the findings of an investigation of the size and morphology controllability in terms of growth kinetics of the NPs in a thermochemical synthesis process. MZF NPs of different sizes were synthesized at different temperatures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!